Nooter K - Search Results

1

Effect of ABCG2 genotype on the oral bioavailability of topotecan.

Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H. Sparreboom A, et al. Among authors: nooter k. Cancer Biol Ther. 2005 Jun;4(6):650-8. doi: 10.4161/cbt.4.6.1731. Epub 2005 Jun 11. Cancer Biol Ther. 2005. PMID: 15908806

2

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Lepper ER, et al. Among authors: nooter k. Pharmacogenomics. 2005 Mar;6(2):115-38. doi: 10.1517/14622416.6.2.115. Pharmacogenomics. 2005. PMID: 15882131 Review.

3

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Burger H, et al. Among authors: nooter k. Cancer Biol Ther. 2005 Jul;4(7):747-52. doi: 10.4161/cbt.4.7.1826. Epub 2005 Jul 9. Cancer Biol Ther. 2005. PMID: 15970668

4

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

Loos WJ, van Zomeren DM, Gelderblom H, Verweij J, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):99-105. doi: 10.1016/s0378-4347(01)00432-7. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11820300

5

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

Loos WJ, Verweij J, Kehrer DF, de Bruijn P, de Groot FM, Hamilton M, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Clin Cancer Res. 2002 Mar;8(3):856-62. Clin Cancer Res. 2002. PMID: 11895919

6

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Anticancer Drugs. 2003 Mar;14(3):227-32. doi: 10.1097/00001813-200303000-00006. Anticancer Drugs. 2003. PMID: 12634617 Clinical Trial.

7

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib.

Burger H, Nooter K. Burger H, et al. Among authors: nooter k. Cell Cycle. 2004 Dec;3(12):1502-5. doi: 10.4161/cc.3.12.1331. Epub 2004 Dec 22. Cell Cycle. 2004. PMID: 15611623

8

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J. Loos WJ, et al. Among authors: nooter k. J Clin Oncol. 2006 Apr 1;24(10):1499-506. doi: 10.1200/JCO.2005.03.0056. J Clin Oncol. 2006. PMID: 16574999 Clinical Trial.

9

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Gardner ER, et al. Among authors: nooter k. Clin Pharmacol Ther. 2006 Aug;80(2):192-201. doi: 10.1016/j.clpt.2006.05.003. Clin Pharmacol Ther. 2006. PMID: 16890580

10

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JH. Ma J, et al. Among authors: nooter k. Br J Cancer. 1998 May;77(10):1645-52. doi: 10.1038/bjc.1998.270. Br J Cancer. 1998. PMID: 9635842 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page